We compared the MicroScan Pos MIC Type 6 panel and AMS-Vitek Gram Positive Susceptibility Card (GPS-TA) to agar dilution screen plates for the detection of high-level aminoglycoside resistance in 182 enterococcal isolates. The specificity of the two commercial systems was 100%, with the exception of one susceptible isolate found to be streptomycin resistant by the Vitek system. The MicroScan and Vitek systems had comparable sensitivities for the detection of gentamicin resistance (90 and 95% respectively) and streptomycin resistance (85 and 78%, respectively). These results suggest that screening tests such as agar dilution screen plates, broth dilution, or disk diffusion should continue to be used to detect high-level gentamicin and streptomycin resistance.
The treatment of bacteremic enterococcal infections is often problematic because of the intrinsic resistance of the organisms to many antimicrobial agents. Enterococci are inhibited but not killed by cell wall-inhibiting antibiotics such as ,-lactams or glycopeptides and are inherently resistant to the aminoglycosides (MICs, 6 to 64 jig/ml) (1, 4) . A combination of a cell wall-inhibiting agent plus an aminoglycoside has been found to be synergistic and effective for the treatment of serious enterococcal infections (1, 5) . However, there is no synergy when an enterococcal strain has highlevel aminoglycoside resistance (MIC, .2,000 jig/ml), and infections due to such organisms may not respond to treatment with such a combination (6, 7) .
Since it was first described in 1979, high-level aminoglycoside resistance among enterococci has increased (3, 6, 7, 13) . Currently, the methods available for the detection of high-level aminoglycoside resistance include single-concentration agar dilution screen plates, disk diffusion, and broth dilution (8, (10) (11) (12) 14 containing 2,000 jig of gentamicin per ml and the other containing 2,000 pLg of streptomycin per ml. The GPS-TA also incorporates two aminoglycoside synergy wells, one containing 500 pLg of gentamicin per ml and the other containing 2,000 jig of streptomycin per ml. We evaluated the accuracy of these two methods, as compared with agar dilution screen plates, for detecting high-level aminoglycoside resistance.
A total of 182 clinical enterococcal isolates collected from blood and sterile body sites had been evaluated as part of a previous study (2) . The isolates were characterized by Gram stain, bile-esculin hydrolysis, and tolerance in the presence of 6.5% sodium chloride and were identified to the species level by MicroScan. Enterococcus faecalis HH22 (gentamicin and streptomycin resistant and P-lactamase positive), UWHC 1921 (gentamicin resistant and streptomycin susceptible), and UWHC 1936 (gentamicin susceptible and streptomycin resistant) (12) were tested as control organisms.
The agar dilution screen plates, which were found previously to accurately detect high-level aminoglycoside resistance (2), contained brain heart infusion agar (GIBCO Diagnostics, Madison, Wis.) and the following concentration of antibiotic: 1,000 ,ug of gentamicin (Schering Corp., Montreal, Quebec, Canada) per ml or 2,000 ,ug of streptomycin (Sigma Chemical Co., St. Louis, Mo.) per ml. All isolates were tested with each antibiotic as previously described (2) . Two to four colonies of each isolate were suspended in brain heart infusion broth and incubated overnight at 35°C to achieve an inoculum of 109 CFU/ml. Using we found the MicroScan and Vitek systems to be comparable for detecting gentamicin and streptomycin resistance. However, the Vitek system was able to provide results in approximately 6 h, whereas the MicroScan system required overnight incubation. Although both systems demonstrated excellent specificity and improved sensitivities, there is still a need to continue using a more accurate technique, such as agar screen dilution plates, broth dilution, or disk diffusion.
